Breakthrough in DES Technology:
Designed to promote early vascular healing, this advanced stent features an ultra-low strut thickness of around 50 μm, minimizing vessel irritation while enhancing endothelialization. Its innovative structure incorporates a variable strut width and crown design, ensuring an optimal balance between flexibility and radial strength, with a robust performance of 1.1 bar. The hybrid cell design offers the best of both worlds—open cells in the middle enable seamless side-branch access, while closed cells at the ends provide superior scaffolding and conformability. Coated with the clinically established drug everolimus and a biodegradable polymer, this stent ensures proven long-term safety and efficacy, supporting superior patient outcomes.
*Bench test data on file at Meril Life Sciences
Key Features
Highlights
- >500 all comer patients studied in 3 clinical studies with follow-up upto 1 year. Ongoing robust clinical trial program
- 0% Stent Thrombosis at 6 months and 1 year in all comer patient population
- Low mace rate of < 2% at 1 year
Indication
Narrowing of a heart's blood vessel can result in its complete blockage and can progress gradually or can occur suddenly resulting in a heart attack, known as a myocardial infarction. Angioplasty is a procedure to widen the coronary artery and restore the blood flow.
Product Details
Connect with Meril
Availability of products may vary by region.
For further details, please contact our support team.